$85MSeries B, 28 January 2026
Equity will fund the US commercial launch of YUVEZZI, expected in early Q2 2026, alongside a separate $150M credit facility.
- Amount
- $85M
- Stage
- Series B
- Announced
- 28 January 2026
- Lead
- Janus Henderson
- Other investors
- EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille
- Use of funds
- Equity will fund the US commercial launch of YUVEZZI, expected in early Q2 2026, alongside a separate $150M credit facility.
- Checked
- Announced by the company
- Sources
- Tenpoint Therapeutics raises $85M Series B plus $150M credit facility ($235M total) sofinnovapartners.com
Tenpoint Therapeutics raises $85M Series B plus $150M credit facility ($235M total) pulse2.com